Therapeutic targeting of non-coding RNAs in cancer

O Slaby, R Laga, O Sedlacek - Biochemical journal, 2017 - portlandpress.com
The majority of the human genome encodes RNAs that do not code for proteins. These non-coding
RNAs (ncRNAs) affect normal expression of the genes, including oncogenes and …

Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells

…, S Viswanathan, A Darinskas, O Slaby… - Stem cells and …, 2012 - liebertpub.com
Mesenchymal stem/stromal cells (MSCs) comprise a heterogeneous population of cells with
multilineage differentiation potential, the ability to modulate oxidative stress, and secrete …

[HTML][HTML] A comprehensive review on MAPK: a promising therapeutic target in cancer

…, L Raduly, A Rusu, A Irimie, AG Atanasov, O Slaby… - Cancers, 2019 - mdpi.com
The mitogen-activated protein kinase (MAPK) pathway is an important bridge in the switch
from extracellular signals to intracellular responses. Alterations of signaling cascades are …

[HTML][HTML] Novel classes of non-coding RNAs and cancer

J Sana, P Faltejskova, M Svoboda, O Slaby - Journal of translational …, 2012 - Springer
For the many years, the central dogma of molecular biology has been that RNA functions
mainly as an informational intermediate between a DNA sequence and its encoded protein. But …

Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer

…, L Radova, M Sachlova, Z Kosarova, K Slaba… - …, 2016 - academic.oup.com
Early detection of colorectal cancer is the main prerequisite for successful treatment and
reduction of mortality. Circulating microRNAs were previously identified as promising diagnostic…

MicroRNA involvement in glioblastoma pathogenesis

J Novakova, O Slaby, R Vyzula, J Michalek - Biochemical and biophysical …, 2009 - Elsevier
MicroRNAs are endogenously expressed regulatory noncoding RNAs. Altered expression
levels of several microRNAs have been observed in glioblastomas. Functions and direct …

[HTML][HTML] Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined …

L Kubiczkova, F Kryukov, O Slaby, E Dementyeva… - …, 2014 - ncbi.nlm.nih.gov
Multiple myeloma still remains incurable in the majority of cases prompting a further search
for new and better prognostic markers. Emerging evidence has suggested that circulating …

Circulating miRNAs as new blood-based biomarkers for solid cancers

M Redova, J Sana, O Slaby - Future oncology, 2013 - Future Medicine
miRNAs are short noncoding RNAs that post-transcriptionally regulate gene expression.
miRNAs’ ability to inhibit translation of oncogenes and tumor suppressor genes implies they …

[HTML][HTML] MicroRNAs in colorectal cancer: translation of molecular biology into clinical application

O Slaby, M Svoboda, J Michalek, R Vyzula - Molecular cancer, 2009 - Springer
MicroRNAs (miRNAs) are small non-coding RNAs 18-25 nucleotides in length that
downregulate gene expression during various crucial cell processes such as apoptosis, …

[HTML][HTML] Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma

…, R Lakomy, M Svoboda, R Vyzula, O Slaby - Journal of translational …, 2012 - Springer
Background There is no standard serum biomarker used for diagnosis or early detection of
recurrence for renal cell carcinoma (RCC) patients. MicroRNAs (miRNAs) are abundant and …